Who Supplies Vancomycin to India from CANADA

Importing finished pharmaceutical formulations containing Vancomycin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) oversees the registration of both the manufacturing site and the product. An Import Registration Certificate is mandatory for each product, and the manufacturing premises must be registered with CDSCO. The application process involves submitting Form 41 for product registration and Form 10 for the import license. The registration certificate is valid for three years and must be renewed nine months before expiration. The application requires a fee of 1,500 USD for the manufacturing unit registration and 1,000 USD for each drug registration. Additional documents include a Free Sale Certificate, Good Manufacturing Practice (GMP) certificate, and Drug Master File (DMF).

Imported Vancomycin formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with each batch accompanied by a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to ICH Zone IV guidelines, must be provided. Port inspection by customs drug inspectors ensures adherence to quality standards. If a batch fails testing, it may be rejected, leading to potential financial losses and reputational damage.

Between 2024 and 2026, the Indian government has implemented the Production Linked Incentive (PLI) scheme to boost domestic manufacturing of pharmaceuticals, potentially reducing reliance on imports. This policy may impact the volume of finished Vancomycin formulations imported from Canada. Additionally, India has engaged in bilateral agreements with Canada to facilitate trade, including mutual recognition of Good Manufacturing Practices (GMP), which may streamline import procedures.

India imports finished Vancomycin formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic manufacturing capacity for Vancomycin is limited, necessitating imports to fulfill market needs. The market size for Vancomycin formulations in India is substantial, with imports valued at approximately $92.2 million across 318 exporters to 140 countries.

The import duty structure for Vancomycin formulations under HS Code 30042096 includes a Basic Customs Duty (BCD) of 10%, a Social Welfare Surcharge (SWS) of 10%, and an Integrated Goods and Services Tax (IGST) of 12%. This results in a total landed duty of approximately 32.4% of the Cost, Insurance, and Freight (CIF) value. Anti-dumping duties and exemptions may apply based on specific circumstances and trade agreements.

India sources Vancomycin formulations from Canada due to the availability of patented formulations, specialized dosage forms, and high-quality products. Canadian manufacturers offer formulations that may not be produced domestically, providing a competitive advantage in the Indian market. Other suppliers include China, Germany, and the United States; however, Canada's share in the Indian market is growing, reflecting its competitive position.

India imports Vancomycin formulations from Canada due to the availability of patented formulations, specialized dosage forms, and high-quality products. Canadian manufacturers offer formulations that may not be produced domestically, providing a competitive advantage in the Indian market. The Production Linked Incentive (PLI) scheme in India may influence this sourcing strategy, as it aims to enhance domestic manufacturing capabilities.

When compared to other origins such as China, the European Union, and the United States, Canada offers competitive advantages in terms of product quality, regulatory compliance, and reliability. Canadian manufacturers adhere to stringent quality standards, ensuring high-quality Vancomycin formulations. The mutual recognition of Good Manufacturing Practices (GMP) between India and Canada further facilitates trade and ensures product quality.

Indian importers face several supply chain risks when sourcing Vancomycin formulations from Canada, including single-source risk, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish robust relationships with suppliers. Monitoring currency exchange rates and staying informed about regulatory changes are also crucial for effective risk management.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source and mitigate supply chain risks.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP), to manage financial risks.
4. 4Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments of their manufacturing facilities and quality control processes.
5. 5Regulatory Compliance: Stay updated on regulatory requirements and ensure that all imports comply with Indian standards and CDSCO guidelines.

1. Directorate General of Foreign Trade (DGFT) Importer Exporter Code (IEC): Obtain an IEC from DGFT to facilitate international trade transactions.